Additional Benefits Versus Practicalities of Beta-Blocker Use in CHF Patients: The 'Some Is Better Than None' Rule

Graham Archard


Br J Cardiol. 2005;12(4):313-317. 

In This Article


Current UK guidelines recommend the routine use of beta blockers in the treatment of chronic heart failure (CHF) but research shows that a large proportion of patients are not prescribed this important therapy. This article details the practical recommendations of the NICE guidelines and stresses the importance of beta blockade, even at low dosage.

Treatments for heart failure include digoxin, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, aldosterone antagonists and beta blockers. Beta blockers have been contra-indicated until fairly recently, with recognition of the role of the sympathetic nervous system in chronic progression of heart damage.

Benefits of beta blockade, proven in clinical trials, include reduction in all-cause mortality, sudden death, hospitalization rates for heart failure, and reversal of some degree of heart damage. Carvedilol and bisoprolol are currently licensed in the UK for chronic heart failure. National Institute for Clinical Excellence (NICE) guidelines give recommendations for initiation of treatment, dose titration and management of adverse effects. Benefits are still apparent in patients who cannot tolerate target drug doses. Several studies show, however, that beta blockers are underprescribed in general practice.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: